Your Current Testosterone Level Is Not Excessive and Requires Dose Adjustment
Your testosterone level of 850 ng/dL is within the normal physiologic range for adult men (300–1,000 ng/dL) but exceeds the recommended therapeutic target of 450–600 ng/dL for testosterone replacement therapy. 1, 2 You should reduce your injection dose to achieve mid-normal levels, which optimize clinical benefit while minimizing adverse effects such as erythrocytosis.
Understanding Your Current Situation
Your Level Is Not "Excessive" But Above Target
The normal testosterone range for adult men is approximately 264–916 ng/dL, with a mean around 500–600 ng/dL. 1 Your level of 850 ng/dL falls within this physiologic range and is not supraphysiologic (which would be >1,000 ng/dL). 1, 2
However, treatment guidelines specifically recommend targeting the middle tertile of the normal range (450–600 ng/dL) rather than the upper range, because this provides optimal symptom relief with the lowest risk of adverse effects. 1, 2
Your baseline of 450 ng/dL was already at the lower end of the target range, so the goal of therapy was to maintain—not dramatically exceed—that level. 1
Why Mid-Normal Levels Are Preferred
Safety Considerations
Erythrocytosis (elevated red blood cell count) is the most common dose-dependent adverse effect of testosterone therapy, occurring in up to 43.8% of men receiving injectable testosterone. 1, 3 Higher testosterone levels increase this risk substantially.
Elevated hematocrit increases blood viscosity, which can worsen coronary, cerebrovascular, and peripheral vascular disease—particularly concerning in men over 50. 1
Injectable testosterone formulations already carry a 3-fold higher erythrocytosis risk compared to transdermal preparations (44% vs. 15%), so maintaining the lowest effective dose is critical. 1, 3
Clinical Efficacy
Studies demonstrate that testosterone therapy produces small but significant improvements in sexual function and libido (standardized mean difference ≈0.35) when levels are normalized to the mid-range. 1 Pushing levels higher does not enhance these benefits.
There is no evidence that testosterone levels in the 700–900 ng/dL range provide superior symptom relief compared to 450–600 ng/dL for the primary indications of diminished libido and erectile dysfunction. 1
Recommended Dose Adjustment Strategy
Immediate Action
Reduce your current injection dose by approximately 40–50% to target a testosterone level of 500–600 ng/dL. 1, 3
- If you are currently injecting 100 mg weekly, reduce to 50–60 mg weekly. 3
- If you are injecting 200 mg every 2 weeks, reduce to 100–120 mg every 2 weeks. 3
Monitoring Schedule
Recheck your testosterone level 2–3 months after the dose reduction, measured midway between injections (days 5–7 for weekly dosing, days 7–10 for bi-weekly dosing). 1, 3, 2
At this visit, also check hematocrit/hemoglobin to ensure you have not developed erythrocytosis. 1 If hematocrit exceeds 54%, testosterone must be withheld and therapeutic phlebotomy considered. 1
Once stable levels in the 450–600 ng/dL range are confirmed, monitor every 6–12 months with testosterone, hematocrit, and PSA (if you are over 40). 1, 2
Why Not Just Continue at 850 ng/dL?
The "Feeling Well" Trap
Many patients report feeling well at higher testosterone levels, but subjective well-being does not protect against objective adverse effects such as erythrocytosis, which develops silently. 1
The goal of testosterone therapy is normalization of levels combined with symptom improvement—not maximization of levels. 2
Long-Term Safety
Supraphysiologic testosterone levels (>1,000 ng/dL) clearly increase adverse event risk, particularly erythrocytosis. 1 While 850 ng/dL is not supraphysiologic, it is higher than necessary and incrementally increases risk without added benefit.
Guidelines emphasize using "the minimal dosing necessary to drive testosterone levels to the normal physiologic range of 450–600 ng/dL." 2
Common Pitfalls to Avoid
Do not continue your current dose simply because you feel well; dose reduction is the appropriate intervention to minimize long-term risks. 1, 3
Do not stop therapy abruptly if you were initially hypogonadal (baseline 450 ng/dL suggests borderline low-normal); dose reduction—not discontinuation—is indicated. 1, 3
Do not skip hematocrit monitoring after dose adjustment; erythrocytosis can develop insidiously and requires surveillance. 1
Do not measure testosterone at the peak (2–5 days post-injection), as this will show transiently elevated levels that do not reflect your average exposure. 1 Always measure midway between injections.
Expected Outcomes After Dose Reduction
Your testosterone level should stabilize in the 500–600 ng/dL range, which is optimal for maintaining the benefits you experienced (improved libido, energy, sexual function) while minimizing erythrocytosis risk. 1, 2
You should continue to experience the modest improvements in sexual function and quality of life that testosterone therapy provides, as these benefits plateau at mid-normal levels. 1
Your risk of developing elevated hematocrit will be substantially lower at the reduced dose. 1, 3